Since assuming office for a second term, President Trump and officials within his administration have instituted a sweeping series of policy actions through the Department of Health and Human Services (HHS) that have fundamentally altered the landscape of public health across the United States. This extensive public resource outlines these key developments in chronological order, capturing the initial announcements alongside their subsequent legal challenges, linked actions, and evolving outcomes. While not exhaustive of every federal policy change with public health implications\u2014many of which originate outside HHS\u2014this tracking details the major shifts in federal healthcare management, scientific research oversight, and disease prevention strategies from early 2025 through late 2026.<\/p>\n
The administration’s public health agenda was signaled immediately upon taking office in January 2025, when President Trump issued a series of Executive Orders revoking prior directives from the Biden administration and establishing new federal guidance regarding gender ideology, diversity, equity, and inclusion (DEI), and merit-based opportunities. These executive actions had an immediate ripple effect on federal data collection and public transparency. In response to the directives, HHS began removing thousands of websites and numerous federal databases containing information deemed related to DEI, LGBTQ+ issues, reproductive health, HIV\/AIDS research, and health disparities. The sudden disappearance of these resources sparked widespread alarm among researchers and public health advocates, culminating in a lawsuit filed by the Washington State Medical Association and other plaintiffs. Although some data was selectively restored over time, the administration formally agreed in September 2025 to restore all previously removed health-focused websites and databases to their January 29, 2025, versions.<\/p>\n
Structural and financial changes to federal research soon followed. On February 7, 2025, the National Institutes of Health (NIH) announced a major policy shift regarding "indirect cost" funding, which supports administration and facilities at grantee research institutions. The agency sought to apply a new 15% standard indirect cost rate on all new and existing grants. This reduction from historical rates prompted immediate legal pushback from state attorneys general, leading to a temporary restraining order, a nationwide preliminary injunction in March, and ultimately a permanent injunction on April 4, 2025. While the administration appealed the ruling, prior rates remained in effect, averting what research institutions warned would be a catastrophic cut to health research funding.<\/p>\n
Leadership at HHS underwent a significant transition on February 13, 2025, when the Senate voted 52-48 along party lines to confirm Robert F. Kennedy, Jr. as the Secretary of Health and Human Services. Concurrently, President Trump issued an Executive Order establishing the Make America Healthy Again (MAHA) policy agenda and the MAHA Commission, naming Secretary Kennedy as its chair. The commission was tasked with assessing the childhood chronic disease crisis within 100 days and formulating an overarching national strategy within 180 days. This initiative set the stage for a series of major shifts focused on combating chronic illnesses such as obesity, diabetes, and mental health disorders by re-evaluating nutritional guidelines, food additives, and environmental factors.<\/p>\n
Concurrently, the White House and the newly formed Department of Government Efficiency (DOGE) initiated workforce reductions across federal agencies, including HHS. These personnel cuts coincided with an Executive Order prohibiting federal funding for any K-12 school or institution of higher education requiring COVID-19 vaccinations for in-person attendance. While state-level vaccine mandates varied, fifteen colleges initially maintained requirements, though all dropped them by mid-March 2025 following the order. <\/p>\n
Secretary Kennedy outlined his broader public health priorities during an HHS welcome ceremony on February 18, 2025, emphasizing an investigation into the childhood vaccine schedule, tackling perceived institutional corruption, and addressing chronic childhood diseases potentially linked to pesticides, food additives, antidepressants, and microplastics. Shortly thereafter, Secretary Kennedy issued a new rule rescinding a long-standing 1971 HHS policy known as the "Richardson Waiver." By re-aligning rulemaking procedures strictly with the Administrative Procedure Act, matters relating to agency management, personnel, loans, grants, benefits, and contracts were exempted from traditional notice-and-comment requirements. While administration officials argued the move streamlined governance, lawmakers and public health groups strongly criticized the loss of public visibility and input on major policy and funding shifts.<\/p>\n
The spring of 2025 brought rapid changes across federal health agencies. In March, HHS announced that the Centers for Disease Control and Prevention (CDC) would conduct a new study into factors contributing to the rise in autism diagnoses. Later that month, the Food and Drug Administration (FDA) released guidance for the 2025-2026 influenza vaccine composition without consulting its outside advisory panel, the Vaccines and Related Biological Products Advisory Committee (VRBPAC), breaking with decades of precedent. Simultaneously, the NIH initiated the termination of numerous grants dedicated to HIV prevention and treatment, including adolescent-focused PrEP research. HHS also removed a 2024 Surgeon General advisory declaring gun violence a public health crisis from its website, and shuttered the White House Office of Gun Violence Prevention while downsizing staff at the CDC\u2019s Injury Center and Division of Violence Prevention.<\/p>\n
Financial disputes between the administration and state health departments escalated in late March when HHS sought to pull back $11.4 billion in supplemental COVID-19 and public health funding previously allocated to state and local health departments. A coalition of 23 Democratic-led states promptly filed suit, leading a federal judge to block the clawback and ultimately restore approximately 80% of the targeted funds to the participating states, while funding remained withheld in non-participating jurisdictions. <\/p>\n
On March 27, 2025, HHS announced a sweeping restructuring plan designed to eliminate 10,000 full-time positions and reorganize major divisions. Proposals included combining multiple offices into a newly minted Administration for a Healthy America (AHA) and transferring the Administration for Strategic Preparedness and Response (ASPR) under the CDC. While a coalition of Democratic-led states challenged the mass layoffs in court, the Supreme Court ultimately overturned lower court injunctions in July, allowing the administration’s workforce reductions to proceed past the 20,000-job threshold. Meanwhile, congressional approval for the structural creation of the AHA stalled.<\/p>\n
Financial restrictions also touched reproductive health and infant safety programs. HHS withheld portions of Title X family planning grants from 23 states, affecting nearly a quarter of all Title X clinics, while Planned Parenthood grantees remained unfunded. On April 1, federal participation in the 30-year-old "Safe to Sleep" infant mortality reduction campaign was terminated alongside the elimination of the NIH Office of Child Health and Human Development communications group. Furthermore, the CDC was ordered to slash its contract spending by $2.9 billion, and Secretary Kennedy announced plans to revisit federal water fluoridation policies, urging states to ban fluoride\u2014a call answered by Utah and Florida later that year.<\/p>\n
Regulatory changes continued through the spring and summer. The FDA required Pfizer and Moderna to expand warning labels on mRNA COVID-19 vaccines regarding myocarditis risks, and joined HHS in initiating voluntary phase-outs of petroleum-based synthetic food dyes. HHS also redirected $500 million from Biden-era COVID-19 vaccine development initiatives toward a "Generation Gold Standard" universal vaccine platform. However, the administration’s fiscal year 2026 budget request proposed deep cuts across the CDC, NIH, HRSA, and SAMHSA. Additionally, an Executive Order restricted federal funding for "gain-of-function" research on biological agents, creating new oversight hurdles for academic and medical institutions.<\/p>\n
In May 2025, the FDA announced that future approvals for new or updated COVID-19 boosters for lower-risk individuals would require randomized, placebo-controlled clinical trials rather than immune-response data alone. Shortly thereafter, the MAHA Commission published its first report on childhood chronic disease, identifying ultra-processed foods, chemicals, physical inactivity, and overmedicalization as primary drivers, though the document faced external criticism over apparent artificial intelligence errors and non-existent citations. The NIH also canceled several early-stage HIV vaccine grants utilizing broadly neutralizing antibody research.<\/p>\n
A major flashpoint occurred on May 27, 2025, when Secretary Kennedy announced via social media that COVID-19 vaccines for healthy children and pregnant women had been removed from the CDC’s recommended immunization schedule. Although the CDC subsequently updated its website to reflect "shared decision-making" guidelines rather than a routine recommendation, professional medical associations filed a federal lawsuit challenging the procedural validity of the change. In June, Secretary Kennedy dismissed all seventeen sitting members of the CDC’s Advisory Committee on Immunization Practices (ACIP), replacing them with new appointees, several of whom had previously expressed skepticism regarding conventional vaccine policies. The newly reconstituted ACIP soon voted to recommend individual decision-making for RSV injections, remove thimerosal from multi-dose flu vaccine vials, and establish workgroups to review the broader childhood immunization schedule.<\/p>\n
Drug approvals and regulatory pathways also saw novel innovations and restrictions. The FDA launched the Commissioner\u2019s National Priority Voucher program to expedite reviews for drugs deemed aligned with U.S. national security and public health interests. Concurrently, the agency approved lenacapavir, a twice-yearly injectable PrEP drug for HIV prevention, which subsequently received World Health Organization pre-qualification to expand access in low- and middle-income nations. However, HHS simultaneously altered program requirements for teen pregnancy prevention and sex education grants, leading to legal challenges from multiple states over rules banning the promotion of gender inclusivity.<\/p>\n
The CDC\u2019s disease surveillance capabilities faced operational cutbacks in July 2025 when the agency deactivated its emergency response for H5N1 avian influenza, limiting human infection reporting to a monthly schedule and halting the public tracking of animal infection rates. Secretary Kennedy also canceled scheduled meetings of the U.S. Preventive Services Task Force (USPSTF), prompting concern among public health organizations regarding the future of preventive service coverage mandated under the Affordable Care Act. Executive leadership at the CDC shifted dramatically when newly confirmed Director Susan Monarez was removed from her post after 28 days following a dispute over vaccine policy implementation and personnel decisions, leaving Deputy HHS Secretary Jim O\u2019Neill to serve as acting director.<\/p>\n
August and September 2025 brought further administrative tightening. HHS barred outside professional medical organizations from participating in ACIP working groups, wound down $500 million in BARDA-funded mRNA vaccine development projects, and reinstated the federal Task Force on Safer Childhood Vaccines. The FDA approved updated 2025-2026 COVID-19 vaccines while restricting their broad approval to individuals aged 65 and older or those at high risk. Meanwhile, the MAHA Commission released its comprehensive strategy document featuring over 120 initiatives to reshape federal health research and nutrition guidelines. Secretary Kennedy renewed the national opioid crisis public health emergency declaration, announced an impending FDA review of mifepristone REMS protocols based on disputed research, and championed new autism initiatives involving the drug leucovorin and warnings concerning acetaminophen use during pregnancy.<\/p>\n
Fall developments included the approval of a generic mifepristone product and the awarding of $60 million in grants for senior fall prevention programs. However, during a federal government shutdown in October, thousands of federal workers received layoff notices, with hundreds of permanent job losses concentrated within the CDC’s injury prevention and health statistics divisions. The FDA also announced new enforcement restrictions on unapproved ingestible fluoride products for children, and later initiated the removal of black box warnings from menopausal hormone replacement therapy products. <\/p>\n
Controversy deepened in November 2025 when the CDC altered its website language to state that a link between vaccines and autism could not be ruled out, drawing widespread condemnation from major medical and scientific societies. Reports also indicated that CDC staff were ordered to end all primate research programs by the end of the year, threatening ongoing HIV and infectious disease prevention studies. Furthermore, internal FDA communications revealed proposals for stricter clinical trial requirements for future vaccines, while ACIP voted to end the universal recommendation for newborns to receive the hepatitis B vaccine birth dose.<\/p>\n
As the administration entered 2026, HHS issued a revised childhood immunization schedule reducing the number of routinely recommended vaccines from seventeen to eleven, shifting several routine immunizations\u2014including rotavirus, influenza, hepatitis A, hepatitis B, and meningococcal vaccines\u2014to shared clinical decision-making. Although federal courts subsequently issued stays and preliminary injunctions blocking several of these vaccine schedule overhauls due to procedural violations, policy friction persisted. BARDA opened solicitations for a $100 million prize program targeting novel antiviral therapies, while the Office of Management and Budget instructed the CDC to cut $600 million in public health funding to Democratic-led states, triggering additional lawsuits and temporary restraining orders.<\/p>\n
The FDA experienced internal reversals and policy adjustments, initially issuing a refusal-to-file letter for Moderna\u2019s seasonal mRNA influenza vaccine before reversing course following further discussions, ultimately leading to a unanimous advisory committee endorsement in June 2026. The agency also announced a broader policy shift making the default requirement for drug approvals results from a single clinical trial rather than two. Meanwhile, the CDC faced internal scrutiny after acting leadership temporarily withheld a study demonstrating high COVID-19 vaccine effectiveness during the winter season before it was ultimately published in an independent medical journal.<\/p>\n
Throughout the spring and summer of 2026, the White House issued further Executive Orders directing HHS to align U.S. childhood vaccine recommendations with practices in peer developed countries and to study single-antigen measles, mumps, and rubella vaccines. Secretary Kennedy terminated remaining COVID-19 Emergency Use Authorization declarations for drugs and medical devices, named eight new members to the long-dormant USPSTF, and instituted a revised mortality-tracking methodology for official CDC measles statistics following public disputes over epidemic death counts. The administration culminated this period by launching agency-wide initiatives focused on vaccine injuries, establishing a specialized clinical research center at the NIH, proposing physician reimbursement for reporting adverse events to the Vaccine Adverse Event Reporting System (VAERS), and modernizing federal safety reporting portals.<\/p>\n","protected":false},"excerpt":{"rendered":"
Since assuming office for a second term, President Trump and officials within his administration have instituted a sweeping series of policy actions through the Department of Health and Human Services (HHS) that have fundamentally altered the landscape of public health across the United States. This extensive public resource outlines these key developments in chronological order, […]<\/p>\n","protected":false},"author":12,"featured_media":1487,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[461],"tags":[1059,2066,870,739,579,244,464,462,162,463,18,203,914,337],"class_list":["post-1488","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-healthcare-and-medical-costs","tag-actions","tag-administration","tag-administrative","tag-changes","tag-comprehensive","tag-health","tag-health-policy","tag-healthcare","tag-insurance","tag-medical-costs","tag-policy","tag-public","tag-tracking","tag-trump"],"_links":{"self":[{"href":"https:\/\/amercanfirstfinance.com\/index.php?rest_route=\/wp\/v2\/posts\/1488","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/amercanfirstfinance.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/amercanfirstfinance.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/amercanfirstfinance.com\/index.php?rest_route=\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/amercanfirstfinance.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1488"}],"version-history":[{"count":0,"href":"https:\/\/amercanfirstfinance.com\/index.php?rest_route=\/wp\/v2\/posts\/1488\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/amercanfirstfinance.com\/index.php?rest_route=\/wp\/v2\/media\/1487"}],"wp:attachment":[{"href":"https:\/\/amercanfirstfinance.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1488"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/amercanfirstfinance.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1488"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/amercanfirstfinance.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1488"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}